结直肠癌患者对含奥沙利铂辅助化疗的耐受性

 目的　对结直肠癌根治术后接受含奥沙利铂(LOHP) 辅助化疗患者的耐受性进行评价。 方法　对2001 年11 月～2008 年1 月在我院接受含LOHP 方案辅助化疗的250 例患者的临床资料进行 回顾性分析。包括三种化疗方案:LOHP 联合持续灌注5 氟尿嘧啶(52Fu) 和甲酰四氢叶酸钙(LV) 的两 周方案( FOL FOX4) 、LOHP 联合快速输注52Fu 和LV 的三周方案(LOHP/ Fu/ LV) 、LOHP 联合口服卡 培他滨的三周方案( XELOX) 。结果　三种方案LOHP 的相对剂量强度分别为99. 4 %、93. 3 %、 100. 5 %。中位完成治疗周期数分别为8 、6 、6 周期。不能耐受不良反应是患者提前终止治疗的主要原 因。恶心(88. 8 %) 、呕吐(45. 6 %) 和外周神经毒性(71. 2 %) 、中性粒细胞下降(38 %) 和血小板下降 (55. 6 %) 是最常见的不良反应。直肠癌患者与结肠癌相比,除了贫血的发生率稍高外,其他不良反应两 组之间无明显差别。结论　本组患者对含奥沙利铂方案辅助化疗的耐受性较西方人差。疗效是否有差 异还需等待生存的随访结果。

Tolerability of Oxalipltin-based Adjuvant Chemotherapy in Colorectal Cancer Patients

Objective 　To analyze the tolerability of oxaliplatin2based adjuvant chemotherapy in colorectal cancer patient s. Methods 　Clinical data of 250 patient s who had received oxaliplatin2based adjuvant chem2 otherapy f rom November 2001 to J anuary 2008 in our hospital were analyzed ret rospectively. There were three different chemotherapy regimens. Bi2weekly oxaliplatin combined with continuous int ravenous in2 fused 5 fluorouracil (52Fu) and leucovorin (LV) ( FOL FOX4) 、t ri2weekly oxaliplatin combined with bolus 52Fu and LV(LOHP/ Fu/ LV) or orally capecitabine (XELOX) . Results 　Relative dose intensity of oxali2 platin were 99. 4 %、93. 3 % and 100. 5 % respectively in these three regimens. The median number of completed t reatment cycles were 8 、6 and 6. The most common cause for withdrawing f rom t reatment early was to be unable to tolerate the adverse effect s (AEs) . Nausea (88. 8 %) 、vomiting (45. 6 %) 、neu2 ropathy (71. 2 %) 、neut ropenia (38 %) and thrombocytopenia (55. 6 %) were the most f requent grade 3 or 4 AEs. Anaemia was more common in rectal cancer patient s than in colon cancer patient s. Conclusion 　Pa2 tient s in our hospital who received oxaliplatin2based adjuvant chemotherapy were less tolerable than in western count ries. It is necessary to us to expect the survival data to show if there are any difference be2 tween our patient s and westerns.